# Cencora, Inc.: Form 10-Q for the period ended Jun 30, 2016

- Company: [Cencora, Inc.](/companies/cor.md) (CIK 1140859)
- Form: 10-Q
- Filed: 2016-08-02
- Accepted by EDGAR: Aug 2, 2016, 19:18 ET
- Period: 2016-06-30
- Accession: 0001140859-16-000011
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1140859/000114085916000011/abc-20160630x10q.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1140859/000114085916000011/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2016-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2016-04-01 to 2016-06-30 | $36.88bn | us-gaap:Revenues |
| Revenue | 9 months, 2015-10-01 to 2016-06-30 | $109.29bn | us-gaap:Revenues |
| Cost of revenue | 3 months, 2016-04-01 to 2016-06-30 | $35.77bn | us-gaap:CostOfGoodsSold |
| Cost of revenue | 9 months, 2015-10-01 to 2016-06-30 | $106.14bn | us-gaap:CostOfGoodsSold |
| Gross profit | 3 months, 2016-04-01 to 2016-06-30 | $1.11bn | us-gaap:GrossProfit |
| Gross profit | 9 months, 2015-10-01 to 2016-06-30 | $3.15bn | us-gaap:GrossProfit |
| Selling, general and administrative | 3 months, 2016-04-01 to 2016-06-30 | $520.0m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months, 2015-10-01 to 2016-06-30 | $1.57bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2016-04-01 to 2016-06-30 | $526.6m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months, 2015-10-01 to 2016-06-30 | $1.30bn | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2016-04-01 to 2016-06-30 | $146.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months, 2015-10-01 to 2016-06-30 | −$81.7m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2016-04-01 to 2016-06-30 | $349.8m | us-gaap:NetIncomeLoss |
| Net income | 9 months, 2015-10-01 to 2016-06-30 | $1.28bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2016-04-01 to 2016-06-30 | $1.56 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months, 2015-10-01 to 2016-06-30 | $5.69 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2016-04-01 to 2016-06-30 | $1.62 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months, 2015-10-01 to 2016-06-30 | $6.12 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2016-04-01 to 2016-06-30 | 224,802,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months, 2015-10-01 to 2016-06-30 | 225,646,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Capital expenditure | 9 months, 2015-10-01 to 2016-06-30 | $310.2m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months, 2015-10-01 to 2016-06-30 | $215.1m | us-gaap:PaymentsOfDividendsCommonStock |
| Share repurchases | 9 months, 2015-10-01 to 2016-06-30 | $1.02bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | at 2016-06-30 | $1.87bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2016-06-30 | $21.46bn | us-gaap:AssetsCurrent |
| Total assets | at 2016-06-30 | $31.91bn | us-gaap:Assets |
| Current liabilities | at 2016-06-30 | $24.00bn | us-gaap:LiabilitiesCurrent |
| Long-term debt | at 2016-06-30 | $3.79bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | at 2016-06-30 | $613.2m | us-gaap:DebtCurrent |
| Shareholders' equity | at 2016-06-30 | $1.88bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 60,812 characters.

### Overview

The following discussion should be read in conjunction with the Consolidated Financial Statements and notes thereto contained herein and in conjunction with the financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015.

We are one of the largest global pharmaceutical sourcing and distribution services companies, helping both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. We deliver innovative programs and services designed to increase the effectiveness and efficiency of the pharmaceutical supply chain in both human and animal health. We are organized based upon the products and services we provide to our customers. Our operations are comprised of the Pharmaceutical Distribution reportable segment and Other.

### Pharmaceutical Distribution Segment

The Pharmaceutical Distribution reportable segment is comprised of two operating segments, which include the operations of AmerisourceBergen Drug Corporation (“ABDC”) and AmerisourceBergen Specialty Group (“ABSG”). Servicing healthcare providers in the pharmaceutical supply channel, the Pharmaceutical Distribution segment’s operations provide drug distribution and related services designed to reduce healthcare costs and improve patient outcomes.

ABDC distributes a comprehensive offering of brand-name and generic pharmaceuticals (including specialty pharmaceutical products), over-the-counter healthcare products, home healthcare supplies and equipment, outsourced compounded sterile preparations, and related services to a wide variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and other alternate site pharmacies, and other customers. ABDC also provides pharmacy management, staffing and other consulting services, and supply management software to a variety of retail and institutional healthcare providers. Additionally, ABDC delivers packaging solutions to institutional and retail healthcare providers.

ABSG, through a number of operating businesses, provides pharmaceutical distribution and other services to physicians who specialize in a variety of disease states, especially oncology, and to other healthcare providers, including hospitals and dialysis clinics. ABSG also distributes plasma and other blood products, injectible pharmaceuticals, vaccines, and other specialty products. Additionally, ABSG provides third party logistics and outcomes research, and other services for biotechnology and other pharmaceutical manufacturers.

Our use of the terms “specialty” and “specialty pharmaceutical products” refers to drugs used to treat complex diseases, such as cancer, diabetes and multiple sclerosis. Specialty pharmaceutical products are part of complex treatment regimens for serious conditions and diseases that generally require ongoing clinical monitoring. We believe the terms “specialty” and “specialty pharmaceutical products” are used consistently by industry participants and our competitors. However, we cannot be certain that other distributors of specialty products define these and other similar terms in exactly the same manner as we do.

Both ABDC and ABSG distribute specialty drugs to their customers, with the principal difference between these two operating segments being that ABSG operates distribution facilities that focus primarily on complex disease treatment regimens. Therefore, a product distributed from one of ABSG’s distribution facilities results in revenue reported under ABSG, and a product distributed from one of ABDC’s distribution centers results in revenue reported under ABDC. Essentially all of ABSG sales consist of specialty pharmaceutical products. ABDC sales of specialty pharmaceutical products have historically been a relatively small component of its overall revenue.

### Other

Other consists of the AmerisourceBergen Consulting Services (“ABCS”) operating segment, the World Courier Group, Inc. (“World Courier”) operating segment, and the MWI Veterinary Supply, Inc. (“MWI”) operating segment. The results of operations of these operating segments are not significant enough to require separate reportable segment disclosure, and therefore, have been included in “Other” for the purpose of our reportable segment presentation.

ABCS, through a number of operating businesses, provides commercialization support services including reimbursement support programs, outcomes research, contract field staffing, patient assistance and co-pay assistance programs, adherence programs, risk mitigation services, and other market access programs to pharmaceutical and biotechnology manufacturers. World Courier, which operates in over 50 countries, is a leading global specialty transportation and logistics provider for the biopharmaceutical industry. MWI is a leading animal health distribution company in the United States and in the United Kingdom. MWI sells pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and various other products to customers in both the companion animal and production animal markets.

### Executive Summary

This executive summary provides highlights from the results of operations that follows:

- Revenue increased 7.7% and 8.8% from the prior year quarter and nine month period, respectively, as a result of ABDC’s increased sales of brand and generic products, and the strong revenue growth of ABSG. The addition of MWI, which was acquired in February 2015, also contributed to the revenue growth in the current year nine month period;
- Pharmaceutical Distribution gross profit increased 6.5% and 4.3% from the prior year quarter and nine month period, respectively, as the result of the contribution from our recent PharMEDium acquisition, and segment revenue growth. Gross profit growth in the current year quarter was adversely impacted by the early renewal of our contract with a significant group purchasing organization (“GPO”) customer at less favorable terms. Gross profit growth in the current year nine month period benefited from the incremental income from ABDC's participation in the WBA global sourcing arrangement and was adversely impacted by lower generic price appreciation and contract renewals with the Department of Defense (“DOD”) and a significant GPO customer at less favorable terms;
- Total gross profit increased 24.3% in the current year quarter primarily due to the reduction of LIFO expense, which was $80.4 million in the current year quarter in comparison to $158.7 million in the prior year quarter and an increased gain from antitrust litigation settlements, which was $121.0 million in the current year quarter in comparison to $43.6 million in the prior year quarter. Total gross profit increased 23.2% in the current year nine month period primarily due to the addition of MWI, a reduction in LIFO expense, which was $274.3 million in the current year nine month period, in comparison to $453.9 million in the prior year nine month period, and an increased gain from antitrust litigation settlements, which was $133.8 million in the current year nine month period, in comparison to $65.1 million in the prior year nine month period;
- Distribution, selling, and administrative expenses increased 3.4% compared to the prior year quarter, primarily due to our November 2015 acquisition of PharMEDium and 15.4% compared to the prior year nine month period, primarily due to the addition of MWI, and to a lesser extent, PharMEDium, and to support our revenue growth;
- Total operating expenses were impacted by Warrants. Warrants income was $83.7 million in the current year quarter and $14.9 million in the prior year quarter. Warrants income was $120.3 million in the current year nine month period compared to Warrants expense of $1,109.2 million in the prior year nine month period. Warrants income in the current year quarter increased primarily due to the decline in our stock price during the quarter ended June 30, 2016. Warrants expense decreased significantly from the prior year nine month period primarily due to the decline in our stock price since June 30, 2015. We also incurred a pension settlement charge during the nine month period ended June 30, 2016 in connection with the settlement of our salaried defined benefit pension plan. In addition, depreciation and amortization expense increased $24.3 million and $91.5 million from the prior year quarter and nine month period, respectively;
- Total segment operating income increased by 8.4% compared to the prior year quarter primarily due to the addition of PharMEDium, and 8.1% compared to the prior year nine month period, primarily due to the additions of MWI and PharMEDium; and
- Income taxes were an expense of $146.9 million and a benefit of $81.7 million in the current year quarter and nine month period, respectively, as compared to an expense of $90.1 million and $297.8 million in the prior year quarter and nine month period, respectively. In November 2015, we received a private letter ruling from the Internal Revenue Service, which entitles us to an income tax deduction equal to the fair value of the Warrants at the date of exercise. As a result, we recognized a tax benefit adjustment of approximately $456 million, which represented the estimated benefit from the tax deduction for the increase in the value of the Warrants from the issuance date through September 30, 2015. This tax benefit adjustment had a significant impact to our effective tax rate in the nine month period ended June 30, 2016. Our income tax rate has also been favorably impacted in fiscal 2016 due to the growth of our international service offerings.

### Results of Operations

### Revenue

*(dollars in thousands)*

|  | Three months ended June 30, 2016 | 2015 | Change | Nine months ended June 30, 2016 | 2015 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution | $35,373,725 | $32,758,828 | 8.0% | $104,734,137 | $97,504,075 | 7.4% |
| Other | 1,576,368 | 1,532,907 | 2.8% | 4,753,988 | 3,214,977 | 47.9% |
| Intersegment eliminations | (68,413) | (58,179) | 17.6% | (199,042) | (227,627) | (12.6)% |
| Revenue | $36,881,680 | $34,233,556 | 7.7% | $109,289,083 | $100,491,425 | 8.8% |

Revenue increased by 7.7% and 8.8% from the prior year quarter and nine month period, respectively. See discussions below under “Pharmaceutical Distribution” and “Other” for commentary regarding our revenue growth.

We currently expect our revenue in fiscal 2016 to increase by approximately 8%. Our future revenue growth will continue to be affected by various factors such as industry growth trends, including drug utilization, the introduction of new innovative brand therapies, the likely increase in the number of generic drugs that will be available over the next few years as a result of the expiration of certain drug patents held by brand-name pharmaceutical manufacturers, price increases and price deflation, general economic conditions in the United States, competition within the industry, customer consolidation, changes in pharmaceutical manufacturer pricing and distribution policies and practices, increased downward pressure on government and other third party reimbursement rates to our customers, and changes in Federal government rules and regulations.

#### Pharmaceutical Distribution Segment

The Pharmaceutical Distribution segment grew its revenue by 8.0% and 7.4% from the prior year quarter and nine month period, respectively. Intrasegment revenues between ABDC and ABSG have been eliminated in the presentation of total Pharmaceutical Distribution revenue. Intrasegment revenues primarily consisted of ABSG sales directly to ABDC customer sites or ABSG sales to ABDC facilities. Intrasegment revenues were $2.0 billion and $1.6 billion in the quarters ended June 30, 2016 and 2015, respectively, and $5.5 billion and $4.7 billion in the nine months ended June 30, 2016 and 2015, respectively.

ABDC’s revenue of $30.1 billion and $89.3 billion in the quarter and nine months ended June 30, 2016 increased 6.5% and 5.7%, respectively, from the prior year periods (before intrasegment eliminations). The increases in ABDC’s revenue were primarily due to overall market growth including sales to WBA. Revenue in the current year quarter and nine month period were negatively impacted by lower sales of products that treat Hepatitis C.

ABSG’s revenue of $7.3 billion and $21.0 billion in the quarter and nine months ended June 30, 2016 increased 20.2% and 17.8%, respectively, from the prior year periods (before intrasegment eliminations). The increases in ABSG’s revenue were due to increased sales in our third party logistics business, the continued growth in our oncology business (including an increase in sales to community oncologists), and increases in our blood products, vaccine and physician office distribution businesses.

A number of our contracts with customers, including group purchasing organizations, are typically subject to expiration each year. We may lose a significant customer if any existing contract with such customer expires without being extended, renewed, or replaced. During the nine months ended June 30, 2016, no significant contracts expired. In June 2016, we signed an agreement with Kaiser Permanente for a five-year term commencing on July 1, 2016 at less favorable terms than the previous contract. Over the next twelve months, no significant contracts are scheduled to expire. Additionally, from time to time, other significant contracts may be renewed prior to their expiration dates. If those contracts are renewed at less favorable terms, they may also negatively impact our revenue, results of operations, and cash flows.

#### Other

Revenue in Other increased 2.8% from the prior year quarter, primarily due to increased revenue from MWI, and increased 47.9% from the prior year nine month period primarily due to the incremental revenue contribution from MWI, which was acquired in February 2015.

### Gross Profit

*(dollars in thousands)*

|  | Three months ended June 30, 2016 | 2015 | Change | Nine months ended June 30, 2016 | 2015 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution | $794,424 | 745,866 | 6.5% | 2,448,601 | 2,347,070 | 4.3% |
| Other | 272,843 | 260,741 | 4.6% | 840,017 | 597,497 | 40.6% |
| Gain from antitrust litigation settlements | 120,960 | 43,567 |  | 133,758 | 65,050 |  |
| LIFO expense | (80,364) | (158,710) |  | (274,305) | (453,878) |  |
| Gross profit | $1,107,863 | $891,464 | 24.3% | $3,148,071 | $2,555,739 | 23.2% |

Gross profit increased 24.3%, or $216.4 million, and 23.2%, or $592.3 million, from the prior year quarter and nine month period, respectively. The increases were due to the increase in gross profit of Pharmaceutical Distribution, the increase in gross profit of Other, the $78.3 million and $179.6 million decrease in LIFO expense from the prior year quarter and nine month period, respectively, and the $77.4 million and $68.7 million increase of gain from antitrust litigation settlements from the prior year quarter and nine month period, respectively. The decreases in LIFO expense were primarily due to lower brand inflation and higher generic drug deflation.

Our cost of goods sold for interim periods includes a last-in, first-out (“LIFO”) provision that is based on our estimated annual LIFO provision. The annual LIFO provision, which we estimate on a quarterly basis, is affected by expected changes in inventory quantities, product mix, and manufacturer pricing practices, which may be impacted by market and other external influences, many of which are difficult to predict. Changes to any of the above factors can have a material impact to our annual LIFO provision.

Pharmaceutical Distribution gross profit increased 6.5%, or $48.6 million, and 4.3%, or $101.5 million, from the prior year quarter and nine month period, respectively. The increases were due to the contribution from our recent PharMEDium acquisition and the growth of our businesses. Gross profit in the current year quarter was adversely impacted by the early renewal of a contract with a significant GPO customer at less favorable terms. Gross profit growth in the current year nine month period benefited from the incremental income from ABDC's participation in the WBA global sourcing arrangement and was adversely impacted by lower generic price appreciation and contract renewals with the DOD and a significant GPO customer at less favorable terms. As a percentage of revenue, Pharmaceutical Distribution gross profit margin of 2.25% and 2.34% in the quarter and nine months ended June 30, 2016 decreased 3 basis points and 7 basis points from the prior year quarter and nine month period, respectively. The decrease from the prior year nine month period was primarily due to a decline in generic price appreciation, contract renewals with the DOD and a significant GPO customer, and increased sales to our larger customers that typically have a lower gross profit margin.

Gross profit in Other increased 4.6%, or $12.1 million, and 40.6%, or $242.5 million, from the prior year quarter and nine month period, respectively. The increase from the prior year quarter was primarily due to the increase in MWI's revenue. The increase from the prior year nine month period was primarily due to the contribution from our February 2015 acquisition of MWI, and, to a lesser extent, the increase in ABCS’s revenue. As a percentage of revenue, gross profit margin in Other of 17.31% in the quarter ended June 30, 2016, increased from 17.01% in the prior year quarter. As a percentage of revenue, gross profit margin in Other of 17.67% in the nine months ended June 30, 2016, decreased from 18.58% in the prior year nine month period. The decrease from the prior year nine month period was primarily due to the addition of MWI, which has a lower gross profit margin in comparison to other businesses within Other.

We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $121.0 million and $43.6 million during the quarters ended June 30, 2016 and 2015, respectively. We recognized gains from antitrust litigation settlements with pharmaceutical manufacturers of $133.8 million and $65.1 million during the nine months ended June 30, 2016 and 2015, respectively. The gains were recorded as reductions to cost of goods sold.

### Operating Expenses

*(dollars in thousands)*

|  | Three months ended June 30, 2016 | 2015 | Change | Nine months ended June 30, 2016 | 2015 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Distribution, selling and administrative | $520,032 | $502,744 | 3.4% | $1,571,088 | $1,361,678 | 15.4% |
| Depreciation and amortization | 92,687 | 68,430 | 35.4% | 265,437 | 173,932 | 52.6% |
| Warrants (income) expense | (83,704) | (14,900) |  | (120,275) | 1,109,211 |  |
| Employee severance, litigation and other | 52,234 | 2,625 |  | 88,719 | 30,999 |  |
| Pension settlement charge | — | — |  | 47,607 | — |  |
| Total operating expenses | $581,249 | $558,899 |  | $1,852,576 | $2,675,820 |  |

Distribution, selling and administrative expenses increased 3.4%, or $17.3 million, from the prior year quarter, primarily due to our November 2015 acquisition of PharMEDium. Distribution, selling and administrative expenses increased 15.4%, or $209.4 million, from the prior year nine month period, primarily due to our February 2015 acquisition of MWI, and to a lesser extent, our November 2015 acquisition of PharMEDium. As a percentage of revenue, distribution, selling and administrative expenses were 1.41% and 1.44% in the current year quarter and nine month period, respectively, and represent an decrease of 6 basis points compared to the prior year quarter and an increase of 8 basis points compared to the prior year nine month period, respectively. The decrease of 6 basis points in comparison to the prior year quarter was primarily due to an initiative to improve operating efficiency across many of our businesses and certain administrative functions. The increase of 8 basis points in comparison to the prior year nine month period was primarily due to the addition of MWI, which has higher operating expenses as a percentage of revenue in comparison to the Pharmaceutical Distribution segment.

Depreciation expense increased 8.6% and 11.2% from the prior year quarter and nine month period, respectively, due to an increase in the amount of capital projects being depreciated. Amortization expense increased 99.9% from prior year quarter primarily due to the amortization of intangible assets from our PharMEDium acquisition. Amortization expense increased 210.2% from the prior year nine month period primarily due to the amortization of intangible assets from our MWI and PharMEDium acquisitions.

Warrants income increased from the prior year quarter primarily due to the decline in our stock price during the quarter ended June 30, 2016. Warrants expense decreased significantly from the prior year nine month period primarily due to the decline in our stock price since June 30, 2015. The Warrants were issued in March 2013 in connection with the agreements and arrangements that define our strategic relationship with WBA. Warrants (income) expense is largely dependent upon changes in our stock price, therefore, future Warrants (income) expense related to the 2017 Warrants could fluctuate significantly. (Refer to “Critical Accounting Policies and Estimates — Warrants” in our Annual Report on Form 10-K for the fiscal year ended September 30, 2015 for a more detailed description of the accounting for the Warrants.)

Employee severance, litigation and other for the quarter ended June 30, 2016 included $34.6 million of employee severance and other costs, a $17.1 million charge related to the transfer of surplus assets from our settled salaried defined benefit pension plan to our defined contribution 401(k) plan, and $0.5 million of deal-related transaction costs. Employee severance, litigation and other for the nine months ended June 30, 2016 included $40.2 million of employee severance and other costs, $18.3 million of deal-related transaction costs (primarily related to professional fees with respect to the PharMEDium acquisition), a $17.1 million charge related to the transfer of surplus assets from our settled salaried defined benefit pension plan to our defined contribution 401(k) plan, and $13.0 million of costs related to customer contract extensions (primarily related to the settlement of certain disputed items). Employee severance, litigation and other for the quarter ended June 30, 2015 included $2.3 million of deal-related transaction costs and $0.4 million of employee severance and other costs. Employee severance, litigation and other for the nine months ended June 30, 2015 included $29.6 million of deal-related transaction costs (primarily related to professional fees with respect to the MWI acquisition) and $1.4 million of employee severance and other costs.

We recorded a pension settlement charge of $47.6 million in the nine month period ended June 30, 2016 related to the settlement of our salaried defined benefit plan (see Note 8).

### Operating Income

*(dollars in thousands)*

|  | Three months ended June 30, 2016 | 2015 | Change | Nine months ended June 30, 2016 | 2015 | Change |
| --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Pharmaceutical Distribution | $410,718 | $377,771 | 8.7% | $1,288,672 | $1,256,747 | 2.5% |
| Other | 82,511 | 77,372 | 6.6% | 272,032 | 186,688 | 45.7% |
| Total segment operating income | 493,229 | 455,143 | 8.4% | 1,560,704 | 1,443,435 | 8.1% |
| Gain from antitrust litigation settlements | 120,960 | 43,567 |  | 133,758 | 65,050 |  |
| LIFO expense | (80,364) | (158,710) |  | (274,305) | (453,878) |  |
| Acquisition-related intangibles amortization | (38,681) | (19,710) |  | (108,611) | (34,478) |  |
| Warrants income (expense) | 83,704 | 14,900 |  | 120,275 | (1,109,211) |  |
| Employee severance, litigation and other | (52,234) | (2,625) |  | (88,719) | (30,999) |  |
| Pension settlement | — | — |  | (47,607) | — |  |
| Operating income (loss) | $526,614 | $332,565 |  | $1,295,495 | $(120,081) |  |

Segment operating income is evaluated before gain from antitrust litigation settlements; LIFO expense; acquisition-related intangibles amortization; Warrants income (expense); employee severance, litigation and other; and the pension settlement.

Pharmaceutical Distribution operating income increased 8.7%, or $32.9 million, and 2.5%, or $31.9 million, from the prior year quarter and nine month period, respectively, due to the increase in gross profit, offset in part by the increase in operating expenses. As a percentage of revenue, Pharmaceutical Distribution operating income margin increased 1 basis point from the prior year quarter primarily due to our initiative to improve operating efficiency. As a percentage of revenue, Pharmaceutical Distribution operating income margin decreased 6 basis points from the prior year nine month period primarily due to a decrease in generic price appreciation, contract renewals with the DOD and a significant GPO customer, and increased sales to our larger customers that typically have a lower gross profit margin.

Operating income in Other increased 6.6%, or $5.1 million, from the prior year quarter, primarily due to the MWI revenue increase, and 45.7%, or $85.3 million, from the prior year nine month period, primarily due to the February 2015 acquisition of MWI.

Interest expense, interest income, and the respective weighted average interest rates in the quarters ended June 30, 2016 and 2015 were as follows (in thousands):

|  | 2016 Amount | Weighted Average Interest Rate | 2015 Amount | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $33,640 | 2.71% | $30,654 | 2.78% |
| Interest income | (1,525) | 0.50% | (861) | 0.16% |
| Interest expense, net | $32,115 |  | $29,793 |  |

Interest expense, interest income, and the respective weighted average interest rates in the nine months ended June 30, 2016 and 2015 were as follows (in thousands):

|  | 2016 Amount | Weighted Average Interest Rate | 2015 Amount | Weighted Average Interest Rate |
| --- | ---: | ---: | ---: | ---: |
| Interest expense | $99,086 | 2.71% | $71,919 | 2.89% |
| Interest income | (2,979) | 0.46% | (1,838) | 0.17% |
| Interest expense, net | $96,107 |  | $70,081 |  |

21

Interest expense, net, increased 7.8%, or $2.3 million, from the prior year quarter and 37.1%, or $26.0 million, from the prior year nine month period due to an increase of $0.5 billion and $1.5 billion in average borrowings from the prior year quarter and nine month period ended June 30, 2015, respectively, primarily due to the February 2015 issuance of senior notes totaling $1.0 billion and the February 2015 and November 2015 variable-rate term loan borrowings to finance a portion of the MWI and PharMEDium acquisitions, respectively. Our average borrowing rate was lower during the current year quarter and nine month period primarily as a result of the recent variable-rate financings, which bear interest at lower rates.

Income tax expense was $146.9 million in the quarter ended June 30, 2016 as compared to $90.1 million in the prior year quarter. Income taxes were a benefit of $81.7 million in the nine month period ended June 30, 2016 as compared to an expense of $297.8 million in the prior year nine month period. In November 2015, we received a private letter ruling from the Internal Revenue Service, which entitles us to an income tax deduction equal to the fair value of the Warrants on the date of exercise. As a result, we recognized a tax benefit adjustment of approximately $456 million, which represented the estimated benefit from the tax deduction for the increase in the fair value of the Warrants from the issuance date through September 30, 2015. This tax benefit adjustment had a significant impact to our effective tax rate in the nine month period ended June 30, 2016. Our income tax rate has also been favorably impacted in fiscal 2016 due to the growth of our international service offerings.

Net income was $349.8 million and $1,284.3 million in the quarter and nine month period ended June 30, 2016, respectively, compared to net income of $214.2 million and a net loss of $499.2 million in the prior year quarter and nine month period, respectively. Net income (loss) for the current and prior year periods has been significantly impacted by Warrants income (expense), net of income taxes.

### Liquidity and Capital Resources

The following table illustrates our debt structure at June 30, 2016, including availability under the multi-currency revolving credit facility, the receivables securitization facility, the revolving credit note and the overdraft facility (in thousands):

| Fixed-Rate Debt: | Outstanding Balance | Additional Availability |
| --- | ---: | ---: |
| $600,000, 1.15% senior notes due 2017 | $599,820 | $— |
| $400,000, 4.875% senior notes due 2019 | 398,718 | — |
| $500,000, 3.50% senior notes due 2021 | 499,621 | — |
| $500,000, 3.40% senior notes due 2024 | 498,884 | — |
| $500,000, 3.25% senior notes due 2025 | 497,704 | — |
| $500,000, 4.25% senior notes due 2045 | 499,109 | — |
| Total fixed-rate debt | 2,993,856 | — |
| **Variable-Rate Debt:** |  |  |
| Revolving credit note | — | 75,000 |
| Receivables securitization facility due 2018 | 500,000 | 950,000 |
| Term loans due in 2020 | 900,000 | — |
| Multi-currency revolving credit facility due 2020 | — | 1,400,000 |
| Overdraft facility due in 2021 (£30,000) | 13,360 | 26,579 |
| Total variable-rate debt | 1,413,360 | 2,451,579 |
| Total debt | $4,407,216 | $2,451,579 |

Our operating results have generated cash flows, which, together with availability under our debt agreements and credit terms from suppliers, has provided sufficient capital resources to finance working capital and cash operating requirements, and to fund capital expenditures, acquisitions, repayment of debt, the payment of interest on outstanding debt, dividends, repurchases of shares of our common stock, and our hedging strategy (see below for further details).

Our primary ongoing cash requirements will be to finance working capital, fund the repayment of debt, fund the payment of interest on debt, fund repurchases of our common stock, fund the payment of dividends, finance acquisitions, and fund capital expenditures and routine growth and expansion through new business opportunities. Future cash flows from operations and borrowings are expected to be sufficient to fund our ongoing cash requirements.

As of June 30, 2016 and September 30, 2015, our cash and cash equivalents held by foreign subsidiaries were $468.6 million and $266.3 million, respectively. We expect that the growth of our cash and cash equivalents held by foreign subsidiaries will generally be based in U.S. dollar denominated holdings. Amounts held by foreign subsidiaries are generally subject to U.S. income taxation on repatriation to the U.S. We do not have any plans to repatriate these amounts back to the U.S., as our foreign subsidiaries intend to indefinitely reinvest this cash in foreign investments or foreign operations.

We have increased seasonal needs related to our inventory build during the December and March quarters that, depending on our cash balance, can require the use of our credit facilities to fund short-term capital needs. Our cash balance in the nine months ended June 30, 2016 needed to be supplemented by intra-period credit facility borrowings to cover short-term working capital needs and a portion of the purchase price of PharMEDium in advance of securing long-term financing. The largest amount of intra-period borrowings under our revolving and securitization credit facilities that was outstanding at any one time during the nine months ended June 30, 2016 was $1,018.2 million. We had $8,273.6 million of cumulative intra-period borrowings under our credit facilities during the nine months ended June 30, 2016. Additionally, we borrowed $500.0 million under our receivables securitization facility that we used to finance principal payments that we elected to make on the November 2015 Term Loan (see below).

We have a $1.4 billion multi-currency senior unsecured revolving credit facility, which expires in November 2020, (“Multi-Currency Revolving Credit Facility”) with a syndicate of lenders. Interest on borrowings under the Multi-Currency Revolving Credit Facility accrues at specified rates based on our debt rating and ranges from 69 basis points to 110 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee, as applicable (91 basis points over CDOR/LIBOR/EURIBOR/Bankers Acceptance Stamping Fee at June 30, 2016) and from 0 basis points to 10 basis points over the alternate base rate and Canadian prime rate, as applicable. We pay facility fees to maintain the availability under the Multi-Currency Revolving Credit Facility at specified rates based on our debt rating, ranging from 6 basis points to 15 basis points, annually, of the total commitment (9 basis points at June 30, 2016). We may choose to repay or reduce our commitments under the Multi-Currency Revolving Credit Facility at any time. The Multi-Currency Revolving Credit Facility contains covenants, including compliance with a financial leverage ratio test, as well as others that impose limitations on, among other things, indebtedness of subsidiaries and asset sales, with which we are compliant as of June 30, 2016.

We have a commercial paper program whereby we may from time to time issue short-term promissory notes in an aggregate amount of up to $1.4 billion at any one time. Amounts available under the program may be borrowed, repaid, and re-borrowed from time to time. The maturities on the notes will vary, but may not exceed 365 days from the date of issuance. The notes will bear interest, if interest bearing, or will be sold at a discount from their face amounts. The commercial paper program does not increase our borrowing capacity as it is fully backed by our Multi-Currency Revolving Credit Facility. There were no borrowings outstanding under our commercial paper program as of June 30, 2016.

We have a receivables securitization facility (“Receivables Securitization Facility”), which expires in November 2018. In June 2016, we amended the Receivables Securitization Facility to increase the borrowing capacity from $950 million to $1,450 million. In June 2016, we utilized the increased capacity to borrow $500 million on the Receivables Securitization Facility to finance $500 million of principal payments that we elected to make on the November 2015 Term Loan, as the Receivables Securitization Facility bears interest at a lower rate. We have available to us an accordion feature whereby the commitment on the Receivables Securitization Facility may be increased by up to $250 million, subject to lender approval, for seasonal needs during the December and March quarters. Interest rates are based on prevailing market rates for short-term commercial paper or LIBOR plus a program fee. We pay a customary unused fee at prevailing market rates, annually, to maintain the availability under the Receivables Securitization Facility. The Receivables Securitization Facility contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we are compliant as of June 30, 2016.

We have an uncommitted, unsecured line of credit available to us pursuant to a revolving credit note (“Revolving Credit Note”). The Revolving Credit Note provides us with the ability to request short-term unsecured revolving credit loans from time to time in a principal amount not to exceed $75 million. The Revolving Credit Note may be decreased or terminated by the bank or us at any time without prior notice. We also have an uncommitted U.K. overdraft facility (“Overdraft Facility”) to fund short term normal trading cycle fluctuations related to our MWI business. In February 2016, we amended the Overdraft Facility to extend the maturity date from November 2016 to February 2021 and increase the borrowing capacity from £20 million to £30 million.

In February 2015, we entered into a variable-rate term loan (“February 2015 Term Loan”), which matures in 2020. Through June 2016, we elected to make principal payments of $575 million on the February 2015 Term Loan, and as a result, our next required principal payment is due upon maturity. The February 2015 Term Loan bears interest at a rate equal either to a base rate plus a margin, or a LIBOR, plus a margin. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over a LIBOR (100 basis points at June 30, 2016) and 0 basis points to 25 basis points over a base rate. The

February 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we are compliant as of June 30, 2016.

In November 2015, we entered into a $1.0 billion variable-rate term loan (the “November 2015 Term Loan”), which matures in 2020. In June 2016, we elected to make principal payments of $500 million on the November 2015 Term Loan, and as a result, our next scheduled principal payment is due upon maturity. The November 2015 Term Loan bears interest at a rate equal either to a base rate, plus a margin, or a LIBOR, plus a margin. The margin is based on our public debt ratings and ranges from 75 basis points to 125 basis points over LIBOR (100 basis points at June 30, 2016) and 0 basis points to 25 basis points over a base rate. The November 2015 Term Loan contains similar covenants to the Multi-Currency Revolving Credit Facility, with which we are compliant as of June 30, 2016. We used the proceeds from the November 2015 Term Loan to finance a portion of the cash consideration paid in connection with the acquisition of PharMEDium.

In August 2013, our board of directors approved a program allowing us to purchase up to $750 million in shares of our common stock. During the six months ended March 31, 2016, we purchased $100.0 million of our common stock under this program. In May 2016, our board of directors authorized a new share repurchase program that, together with availability remaining under the existing August 2013 share repurchase program, permits us to purchase up to $750 million in shares of our common stock, subject to market conditions. During the three months ended June 30, 2016, we purchased $103.1 million of our common stock under the May 2016 program. As of June 30, 2016, we had $646.9 million of availability remaining under the May 2016 repurchase program.

In March 2013, we and WBA entered into various agreements and arrangements pursuant to which subsidiaries of WBA were granted the right to purchase a minority equity position in us, beginning with the right, but not the obligation, to purchase up to 19,859,795 shares of our common stock in open market transactions (approximately 7% of the our common stock on a fully diluted basis as of the date of issuance of the Warrants described below, assuming their exercise in full). In connection with these arrangements, wholly-owned subsidiaries of WBA were issued (a) warrants to purchase up to an aggregate of 22,696,912 shares of our common stock at an exercise price of $51.50 per share, exercisable during a six-month period beginning in March 2016 (the “2016 Warrants”), and (b) warrants to purchase up to 22,696,912 shares of our common stock at an exercise price of $52.50 per share, exercisable during a six-month period beginning in March 2017 (the “2017 Warrants” and, together with the 2016 Warrants, the “Warrants”).

In June 2013, we commenced our hedging strategy by entering into a contract with a financial institution pursuant to which we executed a series of issuer capped call option transactions (“Capped Calls”). The Capped Calls give us the right to buy shares of our common stock subject to the Warrants at specified prices at maturity. The Capped Calls are subject to a “cap” price. If our share price exceeds the “cap” price in the Capped Calls at the time the Capped Calls are exercised, the number of shares that will be delivered to us under the Capped Calls will be reduced accordingly. This hedge transaction was completed in January 2014, and included the purchase of Capped Calls on a total of 27.2 million shares of our common stock for a total premium of $368.7 million.

Subsequently, we amended certain of the Capped Calls to increase their “cap” price to continue to address the dilutive effect of the Warrants. We paid a premium of $100.0 million in January 2015 to increase the cap price on certain of the Capped Calls subject to the 2016 Warrants. The Capped Calls permit us to acquire shares of our common stock at strike prices of $51.50 and $52.50 and have expiration dates ranging from February 2016 through October 2017. The Capped Calls permit net share settlement, which is limited by caps on the market price of our common stock. We accounted for the Capped Calls as equity contracts and therefore the above premiums were recorded as a reduction to paid-in capital.

In fiscal 2014 and 2015, we purchased $1,774.1 million of our common stock under special share repurchase programs to further mitigate the potentially dilutive effect of the Warrants and supplement our previously executed warrant hedging strategy.

In March 2015, we supplemented our hedging strategy by entering into a contract with a financial institution pursuant to which we executed a series of issuer call options (“Call Options”). The Call Options gave us the right to buy shares of our common stock subject to the Warrants at specified prices between April 2015 and October 2015. In total, we purchased Call Options on six million shares of our common stock for a total premium of $80.0 million. We accounted for the Call Options as equity contracts and therefore, the above premium was recorded as a reduction to paid-in capital.

In September 2015, our board of directors authorized a new special share repurchase program allowing us to purchase up to $2.4 billion in shares of our common stock, subject to market conditions. During the nine months ended June 30, 2016, we purchased $820.0 million of our common stock (all under the Call Options and Capped Calls) under this program. We had $1,455.9 million of availability remaining under this special share repurchase program as of June 30, 2016. Availability under the special share repurchase program is reduced by share repurchases, if any, of our common stock on the open market under the special program, as well as share repurchases due to our exercise of Call Options and/or Capped Calls.

In March 2016, the 2016 Warrants were exercised for $1,168.9 million in cash. The earnings per share dilutive effect of the 2016 Warrants was fully mitigated by our hedging a portion of our obligation to deliver common stock with a financial institution and repurchasing additional shares of our common stock under special share repurchase program for our own account over time (see above).

The following table illustrates the dilutive impact of the 2017 Warrants based on the closing price of our common stock on June 30, 2016:

*(in thousands)*

|  |  |
| --- | ---: |
| Warrants Exercisable | 22,697 |
| Shares repurchased under special share repurchase program through June 30, 2016 | 10,447 |
| Shares expected to be repurchased under remaining Capped Calls | 13,620 |
| Total repurchases | 24,067 |
| Warrants Coverage | 106% |

To the extent the remaining Capped Calls do not fully mitigate the dilutive effect of the Warrants, we intend to consider repurchasing additional shares of our common stock and other measures, which may include additional amendments to the Capped Calls or the purchase of additional Call Options. The amount of dilution that we would be able to mitigate will depend on the relative costs and benefits of such a transaction, considering factors such as: our financial performance, the current and future share price of our common stock, our expected cash flows, competing priorities for capital, and overall market conditions.

We have market risk exposure to interest rate fluctuations relating to our debt. We manage interest rate risk by using a combination of fixed-rate and variable-rate debt. The amount of variable-rate debt fluctuates during the year based on our working capital requirements. In the nine months ended June 30, 2016, we used a $1.0 billion variable rate term loan to finance a portion of the PharMEDium acquisition price. We also borrowed $500 million from the Receivables Securitization Facility to finance $500 million of principal payments that we elected to make on the November 2015 Term Loan. We periodically evaluate financial instruments to manage our exposure to fixed and variable interest rates. However, there are no assurances that such instruments will be available in the combinations we want and on terms acceptable to us. There were no such financial instruments in effect at June 30, 2016.

We also have market risk exposure to interest rate fluctuations relating to our cash and cash equivalents. We had $1,865.2 million in cash and cash equivalents at June 30, 2016. The unfavorable impact of a hypothetical decrease in interest rates on cash and cash equivalents would be partially offset by the favorable impact of such a decrease on variable-rate debt. For every $100 million of cash invested that is in excess of variable-rate debt, a 10 basis point decrease in interest rates would increase our annual net interest expense by $0.1 million.

We have minimal exposure to foreign currency and exchange rate risk from our non-U.S. operations. Our largest exposure to foreign exchange rates exists primarily with the Euro, the U.K. Pound Sterling, the Canadian Dollar, and the Brazilian Real. Revenue from our foreign operations is less than one percent of our consolidated revenue. We may utilize foreign currency denominated forward contracts to hedge against changes in foreign exchange rates. We may use derivative instruments to hedge our foreign currency exposure, but not for speculative or trading purposes. As of June 30, 2016, we had one foreign currency denominated contract outstanding that hedges the foreign currency exchange risk of a C$39.8 million outstanding note that we received in conjunction with the sale of a Canadian business in May 2013.

Changes in the price and volatility of our common stock may have a significant impact on the fair value of the Warrants issued to WBA and the related tax benefit. As of June 30, 2016, a one dollar change in our common stock, holding other assumptions constant, would increase or decrease the fair value of the Warrants by approximately $22 million and a one percent change in volatility, holding other assumptions constant, would increase or decrease the fair value of the Warrants by approximately $1 million.

Following is a summary of our contractual obligations for future principal and interest payments on our debt, minimum rental payments on our noncancelable operating leases and minimum payments on our other commitments at June 30, 2016 (in thousands):

|  | Payments Due by Period Total | Within 1 Year | 1-3 Years | 4-5 Years | After 5 Years |
| --- | ---: | ---: | ---: | ---: | ---: |
| Debt, including interest payments | $5,559,905 | $732,555 | $720,786 | $1,471,814 | $2,634,750 |
| Operating leases | 519,387 | 84,660 | 156,691 | 113,703 | 164,333 |
| Other commitments | 97,029 | 64,611 | 29,909 | 2,509 | — |
| Total | $6,176,321 | $881,826 | $907,386 | $1,588,026 | $2,799,083 |

We outsource to IBM Global Services a portion of our corporate and ABDC data center operations. The remaining commitment under our arrangement, which expires in June 2018, is approximately $44.9 million as of June 30, 2016, of which $22.9 million represents our commitment over the next twelve months, and is included in “Other commitments” in the above table.

We have commitments to purchase product from influenza vaccine manufacturers through the 2016/2017 flu season. We are required to purchase doses at prices that we believe will represent market prices. We currently estimate our remaining purchase commitment under these agreements will be approximately $34.5 million as of June 30, 2016, all of which represents our commitment over the next twelve months, and are included in "Other commitments" in the above table.

Our liability for uncertain tax positions was $63.1 million (including interest and penalties) as of June 30, 2016. This liability represents an estimate of tax positions that we have taken in our tax returns which may ultimately not be sustained upon examination by taxing authorities. Since the amount and timing of any future cash settlements cannot be predicted with reasonable certainty, the estimated liability has been excluded from the above contractual obligations table.

During the nine months ended June 30, 2016, our operating activities provided $1,822.0 million of cash in comparison to cash provided of $2,760.3 million in the prior year period. Cash provided by operations during the nine months ended June 30, 2016 was principally the result of net income of $1,284.3 million and an increase in accounts payable, accrued expenses, and income taxes of $1,812.3 million, offset, in part by an increase in accounts receivable of $705.5 million and an increase in merchandise inventories of $675.6 million. The increase in accounts payable, accrued expenses and income taxes was primarily driven by the increase in merchandise inventories and the timing of payments to our suppliers. We also increased our merchandise inventories at June 30, 2016 to support the increase in business volume. Accounts receivable increased as a result of our revenue growth, including additional sales to WBA.

We use days sales outstanding, days inventory on hand, and days payable outstanding to evaluate our working capital performance. The below financial metrics are calculated based upon a quarterly average and can be impacted by the timing of cash receipts and disbursements, which can vary significantly depending upon the day of the week in which the month ends.

|  | Three months ended June 30, 2016 | 2015 | Nine months ended June 30, 2016 | 2015 |
| --- | ---: | ---: | ---: | ---: |
| Days sales outstanding | 21.6 | 20.5 | 21.4 | 19.8 |
| Days inventory on hand | 29.8 | 29.6 | 30.2 | 30.0 |
| Days payable outstanding | 57.7 | 54.0 | 56.7 | 51.4 |

The increase in days payable outstanding from the prior year periods has benefited from the increase in purchases of generic pharmaceuticals, which have longer payment terms than brand-name pharmaceuticals.

Our cash flows from operating activities can vary significantly from period to period based on fluctuations in our period end working capital. Additionally, any changes to payment terms with a significant customer or manufacturer supplier could have a material impact to our cash flows from operations. We expect our days sales outstanding to increase in the remainder of fiscal 2016 and in fiscal 2017 as the result of a gradual change in payment terms with our largest customer. Operating cash flows during the nine months ended June 30, 2016 included $97.7 million of interest payments and $0.4 million of income tax refunds, net of payments. Operating cash flows during the nine months ended June 30, 2015 included $67.5 million of interest payments and $199.2 million of income tax payments, net of refunds.

During the nine months ended June 30, 2015, our operating activities provided $2,760.3 million of cash. Cash provided by operations during the nine months ended June 30, 2015 was principally the result of an increase in accounts payable, accrued expenses, and income taxes of $3,530.8 million and non-cash items of $1,314.0 million, offset, in part by the net loss of $499.2 million, an increase in accounts receivable of $868.7 million, and an increase in merchandise inventories of $700.3 million. The non-cash items were comprised primarily of $1,109.2 million of Warrants expense. The increase in accounts payable, accrued expenses and income taxes was primarily driven by the increase in merchandise inventories and the timing of payments to our suppliers. Accounts receivable increased, reflecting our increased revenue volume, including additional sales to WBA. We also increased our merchandise inventories at June 30, 2015 to support the increase in business volume.

Capital expenditures for the nine months ended June 30, 2016 and 2015 were $310.2 million and $157.1 million, respectively. Significant capital expenditures in the nine months ended June 30, 2016 included technology initiatives, including costs related to the development of track-and-trace technology, costs associated with expanding distribution capacity, and expansion of support facilities. We currently expect to spend approximately $400 million for capital expenditures during fiscal 2016. Significant capital expenditures in the nine months ended June 30, 2015 included technology initiatives, including costs related to the further development of our enterprise resource planning system, costs associated with building our new national distribution center, and expansion of support facilities.

Net cash provided by financing activities in fiscal 2016 included $1,168.9 million received upon the exercise of the 2016 Warrants by WBA and $1.0 billion of borrowings under our November 2015 Term Loan. We used the proceeds from the November 2015 Term Loan to fund a portion of our November 2015 acquisition of PharMEDium. We used a portion of the proceeds from the exercise of the 2016 Warrants to purchase our common stock under our special share repurchase program. During the nine months ended June 30, 2016 and 2015, we paid $1,023.1 million and $800.3 million, respectively, for purchases of our common stock.

In November 2014, our board of directors increased the quarterly cash dividend by 23% from $0.235 per share to $0.29 per share. In November 2015, our board of directors increased the quarterly cash dividend by 17% from $0.29 per share to $0.34 per share. We anticipate that we will continue to pay quarterly cash dividends in the future. However, the payment and amount of future dividends remains within the discretion of our board of directors and will depend upon our future earnings, financial condition, capital requirements, and other factors.

### Cautionary Note Regarding Forward-Looking Statements

Certain of the statements contained in this Management’s Discussion and Analysis of Financial Condition and Results of Operations and elsewhere in this report are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Words such as “expect,” “likely,” “outlook,” “forecast,” “would,” “could,” “should,” “can,” “will,” “project,” “intend,” “plan,” “continue,” “sustain,” “synergy,” “on track,” “believe,” “seek,” “estimate,” “anticipate,” “may,” “possible,” “assume,” variations of such words, and similar expressions are intended to identify such forward-looking statements. These statements are based on management’s current expectations and are subject to uncertainty and change in circumstances. These statements are not guarantees of future performance and are based on assumptions that could prove incorrect or could cause actual results to vary materially from those indicated. Among the factors that could cause actual results to differ materially from those projected, anticipated, or implied are the following: competition; industry consolidation of both customers and suppliers resulting in increasing pressure to reduce prices for our products and services; changes in pharmaceutical market growth rates; price inflation in branded and generic pharmaceuticals, and price deflation in generics; declining economic conditions in the United States and abroad; financial market volatility and disruption; substantial defaults in payment, material reduction in purchases by or the loss, bankruptcy or insolvency of a major customer; the loss, bankruptcy or insolvency of a major supplier; changes to the customer or supplier mix; the retention of key customer or supplier relationships under less favorable economics or the adverse resolution of any contract or other dispute with customers or suppliers; changes to customer or supplier payment terms; changes in any of the economic models used by any of our suppliers to set pricing and/or other terms for the purchase of pharmaceuticals; interest rate and foreign currency exchange rate fluctuations; the disruption of AmerisourceBergen’s cash flow and ability to return value to its stockholders in accordance with its past practices; risks associated with the strategic, long-term relationship between Walgreens Boots Alliance, Inc. and AmerisourceBergen, including with respect to the pharmaceutical distribution agreement and/or the global sourcing arrangement; risks associated with the potential impact on AmerisourceBergen’s earnings per share resulting from the issuance of the warrants to subsidiaries of Walgreens Boots Alliance, Inc. (the “Warrants”); AmerisourceBergen’s inability to fully implement its hedging strategy to mitigate the potentially dilutive effect of the issuance of its common stock in accordance with the Warrants under its special share repurchase program due to its financial performance, the current and future share price of its common stock, its expected cash flows, competing priorities for capital, and overall market conditions; changes in the United States healthcare and regulatory environment, including changes that could impact prescription drug reimbursement under Medicare and Medicaid; increasing governmental regulations regarding the pharmaceutical supply channel and pharmaceutical compounding; federal and state government enforcement initiatives to detect and prevent suspicious orders of controlled substances and the diversion of controlled substances; federal and state prosecution of alleged violations of related laws and regulations, and any related litigation, including shareholder derivative lawsuits or other disputes relating to our distribution of controlled substances; increased federal scrutiny and qui tam litigation for alleged violations of fraud and abuse laws and regulations and/or any other laws and regulations governing the marketing, sale, purchase and/or dispensing of pharmaceutical products or services and any related litigation; material adverse resolution of pending legal proceedings; declining reimbursement rates for pharmaceuticals; the acquisition of businesses that do not perform as expected, or that are difficult to integrate or control, including the integration of MWI and PharMEDium, or the inability to capture all of the anticipated synergies related thereto; managing foreign expansion, including non-compliance with the U.S. Foreign Corrupt Practices Act, anti-bribery laws and economic sanctions and import laws and regulations; malfunction, failure or breach of sophisticated information systems to operate as designed; risks generally associated with data privacy regulation and the international transfer of personal data; changes in tax laws or legislative initiatives that could adversely affect AmerisourceBergen’s tax positions and/or AmerisourceBergen’s tax liabilities or adverse resolution of challenges to AmerisourceBergen’s tax positions; natural disasters or other unexpected events that affect AmerisourceBergen’s operations; the impairment of goodwill or other intangible assets, resulting in a charge to earnings; errors in the production, labeling or packaging of products compounded by our compounded sterile preparations (CSP) business; and other economic, business, competitive, legal, tax, regulatory and/or operational factors affecting AmerisourceBergen’s business generally. Certain additional factors that management believes could cause actual outcomes and results to differ materially from those described in forward-looking statements are set forth (i) elsewhere in this report, (ii) in Item 1A (Risk Factors), in the Company’s Annual Report on Form 10-K for the fiscal year ended September 30, 2015 and elsewhere in that report and (iii) in other reports filed by the Company pursuant to the Securities Exchange Act.

## Market risk

As filed, 262 characters.

The Company’s most significant market risks are the effects of changing interest rates, foreign currency risk, and changes in the price and volatility of the Company’s common stock. See the discussion under “Liquidity and Capital Resources” in Item 2 on page 22.

## Controls and procedures

As filed, 1,359 characters.

### Evaluation of Disclosure Controls and Procedures

The Company maintains disclosure controls and procedures that are intended to ensure that information required to be disclosed in the Company’s reports submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. These controls and procedures also are intended to ensure that information required to be disclosed in such reports is accumulated and communicated to management to allow timely decisions regarding required disclosures.

The Company’s Chief Executive Officer and Chief Financial Officer, with the participation of other members of the Company’s management, have evaluated the effectiveness of the Company’s disclosure controls and procedures (as such term is defined in Rules 13a — 15(e) and 15d — 15(e) under the Exchange Act) and have concluded that the Company’s disclosure controls and procedures were effective for their intended purposes as of the end of the period covered by this report.

### Changes in Internal Control over Financial Reporting

During the third quarter of fiscal 2016, there was no change in AmerisourceBergen Corporation’s internal control over financial reporting that materially affected, or is reasonably likely to materially affect, internal control over financial reporting.

## Risk factors

As filed, 141 characters.

Our significant business risks are described in Item 1A to Form 10-K for the year ended September 30, 2015 to which reference is made herein.

Filed Aug 2, 2016.
Source: SEC EDGAR, the filing index for accession 0001140859-16-000011. Last ingested by Listed: Nov 15, 2026, 01:23 ET. No prices; not investment advice.
